Purpose: To explore the role of serum interleukin-16 (IL-16) in the occurrence of multiple myeloma (MM) and after the success chemotherapy and its clinical significance.
Methods: 52 cases of MM patients, 30 cases of AML patients and 30 healthy volunteers from Jan. 2011 to Jan.